20 mg tablet: A brown speckled, biconvex oval tablet with a score on one face separating the debossed
number ‘20' on one half and the letters ‘MG' on the other half; the letter ‘G' is debossed on the other
The tablet can be divided into equal halves.
Indications for use, specifying the target species
For the treatment of pain associated with mild to moderate osteoarthritis in dogs.
Do not use in case of hypersensitivity to the active substance or any of the excipients. Do not use in pregnant, lactating or breeding animals, see section below.
Special warnings for each target species
The majority of clinical cases assessed in the clinical field studies suffered from mild to moderate osteoarthritis based on the veterinary assessment. To achieve a substantiated response to treatment, use the veterinary medicinal product only in mild and moderate cases of osteoarthritis.
From the two clinical field studies, the overall success rates based on CBPI (Canine Brief Pain Inventory, as completed by the owner) at 28 days after the start of the treatment, were 51.3% (120/235) for Galliprant and 35.5% (82/231) for the placebo group. This difference in favour of Galliprant was statistically significant (p-value= 0.0008).
A clinical response to treatment is usually seen within 7 days. If no clinical improvement is apparent after 14 days, treatment with Galliprant should be iscontinued and different treatment options should be explored in consultation with the veterinarian.